Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (75%) |
| Double-patenting only | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN DRUFF, SYDNEY | 1 | 57.2% | +28.5% |
| CHU, CHRIS H | 1 | 53.1% | +9.6% |
| DENT, ALANA HARRIS | 1 | 44.6% | +32.4% |
| DICKINSON, PAUL W | 1 | 63.0% | +9.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18651929 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | VAN DRUFF, SYDNEY | 26d overdue |
| 17625226 | Intratumoral TFR Cells Curtail Anti-PD-1 Treatment Efficacy | DENT, ALANA HARRIS | 84d |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 2874 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18651929 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | VAN DRUFF, SYDNEY | 1643 | §103 | Non-Final OA | 26d overdue | Pending | May 01, 2024 |
| 18245273 | HOLLOW CORE OPTICAL WAVEGUIDES AND METHODS FOR MODIFICATION THEREOF | CHU, CHRIS H | 2874 | §103 | Non-Final OA | 33d | Pending | Mar 14, 2023 |
| 17625226 | Intratumoral TFR Cells Curtail Anti-PD-1 Treatment Efficacy | DENT, ALANA HARRIS | 1643 | DP | Non-Final OA | 84d | Pending | Jan 06, 2022 |
| 17440067 | PEPTIDE-INDUCED NK CELL ACTIVATION | DICKINSON, PAUL W | 1618 | §103 | Non-Final OA | 27d | Pending | Sep 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial